Suhag faculty of medicine
Sohag, Sohag Governorate, 0123, Egypt
NCT Number: NCT07519694
Peribulbar block, is the favored anesthetic technique for numerous ophthalmic procedures due to its lower rate of associated complications .
Retinal surgeries have many problems to the anesthesiologists as these operations are often lengthy , involve a significant risk of postoperative pain ,and typically involve an elderly patient population with multiple comorbidities .
Many anesthesiologists consider the peribulbar block as a safe technique; however, it has the disadvantage of a slow onset of orbital akinesia and to produce it a more substantial volume or repeated injections of local anesthetic solution is required due to limited diffusion of local anesthetics . This also increases the frequency of complications, such as globe perforation and peribulbar hemorrhage .
To prevent this and to increase tissue perfusion, hyaluronidase and other adjuvants such as clonidine, epinephrine and alkalinization of local anesthetics were used to improve peribulbar block.
Hyaluronidase may reduce tissue viscosity , which facilitate the complete diffusion of anesthetic solution along tissue planes .
in regional anesthesia is the addition of hyaluronidase is associated with benefits such as faster onest of action and impoved block quality ,however ,evidence regarding its efficacy in peribulbar techniques remains inconsistent.
To improve the quality and duration of the block, various adjuvants have been investigated. Two promising agents are Midazolam, a benzodiazepine with hypothesized peripheral GABA-ergic action, and Cisatracurium, a non-depolarizing neuromuscular blocking agent. Midazolam may enhance sensory block and provide amnesia, while cisatracurium directly induces chemical paralysis of the extraocular muscles. However, a direct comparative study of their efficacy and safety profiles in this context is lacking. This study aims to fill that gap .
90 eligible patients were randomly allocated into three groups using computer-generated random numbers placed in sealed, opaque envelopes.
* Group L (Control): lidocaine 2٪ (4 ml) + Normal Saline (1 ml). * Group M (Midazolam): lidocaine 2٪ % (4 ml) + Midazolam (1 mg in 1 ml). * Group C (Cisatracurium): lidocaine 2٪ (4 ml) + Cisatracurium (0.5 mg in 0.5 ml) + Normal Saline (0.5 ml).
The total volume of the injectate was standardized to 5 ml for all groups.
Trial opening soon.
Get Notified18 year–70 year
All sexes
Interventional
Not applicable
Sohag, Sohag Governorate, 0123, Egypt
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
peribulber injection of idocaine 2٪ % (4 ml) + Midazolam (1 mg in 1 ml).
peribulber injection of lidocaine 2٪ (4 ml) + Cisatracurium (0.5 mg in 0.5 ml) + Normal Saline (0.5 ml).
peribulber injection of lidocaine 2٪ (4 ml) + Normal Saline (1 ml).
Time frame: investigator assess muscle tone immediately after start of anesthesia and every 15 minute up to end of surgery
onset of muscle paralysis (loss of muscle tone)
Contact information is provided by the study sponsor or research team.
ahmed hamody hasan, assistant professor
CONTACT
waleed adel Ahmed, lecturer
CONTACT
Sohag University
Other
Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery (Prospective Comparative Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04371445
Neurologic Manifestations, Ocular Inflammation
Cleveland, Ohio, United States
View Trial DetailsNCT03390244
Vitreoretinal Surgery
Leuven, Vl-Brabant, Belgium
View Trial DetailsNCT04412525
Vitreoretinal Surgery
Leuven, Belgium
View Trial DetailsNCT04216108
Vitreoretinal Surgery
Leuven, Vl-Brabant, Belgium
View Trial Details